Oxazaphosphorines
303
88. Anderson L, Chen T-L, Colvin OM, et al. Cyclophosphamide
and 4-hydroxycyclophosphamide/aldophosphamide kinetics
in patients receiving high-dose cyclophosphamide chemothe-
rapy. Clin Cancer Res 1996; 2: 1481-7
89. Williams ML, Wainer IW, Embree L, et al. Enantioselective
induction of cyclophosphamide metabolism by phenytoin. Chi-
rality 1999; 11: 569-74
106. Lind MJ, Margison JM, Cerny T, et al. Comparative pharmaco-
kinetics and alkylating activity of fractionated intravenous
and oral ifosfamide in patients with bronchogenic carcinoma.
Cancer Res 1989; 49: 753-7
107. Kurowski V, Cerny T, Küpfer A, et al. Metabolism and pharma-
cokinetics of oral and intravenous ifosfamide. J Cancer Res
Clin Oncol 1991; 117 Suppl. 4: S148-S53
108. Aeschlimann C, Kupfer A, Schefer H, et al. Comparative phar-
macokinetics of oral and intravenous ifosfamide/mesna/
methylene blue therapy. Drug Metab Disp 1998; 26: 883-90
109. Lind MJ, Roberts HL, Thatcher N, et al. The effect of route of
administration and fractionation of dose on the metabolism
of ifosfamide. Cancer Chemother Pharmacol 1990; 26: 105-11
110. Cerny T, Küpfer A. The enigma of ifosfamide encephalopathy.
Ann Oncol 1992; 3: 679-81
111. Cerny T, Lind M, Thatcher N, et al. A simple outpatient treat-
ment with oral ifosfamide and oral etoposide for patients with
small cell lung cancer (SCLC). Br J Cancer 1989; 60: 258-61
112. Lewis LD. A study of 5 day fractionated ifosfamide pharmaco-
kinetics in consecutive treatment cycles. Br J Clin Pharmacol
1996; 42: 179-86
113. Comandone A, Leone L, Oliva C, et al. Pharmacokinetics of
ifosfamide administered according to three different sched-
ules in metastatic solft tissue and bone sarcomas. J Chemo-
therapy 1998; 10: 385-93
114. Boddy AV, Yule SM, Wyllie R, et al. Comparison of continuous
infusion and bolus administration of ifosfamide in children.
Eur J Cancer 1995; 31A: 785-90
115. Singer J, Hartley J, Brennan C, et al. The pharmacokinetics and
metabolism of ifosfamide during bolus and infusional admin-
istration: a randomised cross-over study. Br J Cancer 1998;
77: 978-84
116. Lind MJ, Margison JM, Cerny T, et al. Prolongation of ifosfam-
ide elimination half-life in obese patients due to altered drug
distribution. Cancer Chemother Pharmacol 1989; 25: 139-42
117. Boddy AV, Yule SM, Wyllie R, et al. Pharmacokinetics and
metabolism in children of ifosfamide administered as a con-
tinuous infusion. Cancer Res 1993; 53: 3758-64
90. Kennedy MJ, Zahurak ML, Donehower RC, et al. Sequence-
dependent hematological toxicity associated with the 3-hour
paclitaxel/cyclophosphamide doublet. Clin Cancer Res 1998;
4: 349-56
91. Holm KA, Kindberg CG, Stobaugh JF, et al. Stereoselective
pharmacokinetics and metabolism of the enantiomers of cy-
clophosphamide. Preliminary results in humans and rabbits.
Biochem Pharmacol 1990; 39: 1375-84
92. Williams ML, Wainer IW, Granvil CP, et al. Pharmacokinetics
of (R)- and (S)-cyclophosphamide and their dechloroethyl-
ated metabolites in cancer patients. Chirality 1999; 11: 301-8
93. Busse D, Busch FW, Schweizer E, et al. Fractionated admin-
istration of high-dose cyclophosphamide: influence on dose-
dependent changes in pharmacokinetics and metabolism.
Cancer Chemother Pharmacol 1998; 43: 263-8
94. Huitema ADR, Kerbusch T, Tibben MM, et al. Modelling of the
pharmacokinetics (PK) and auto-induction of high-dose cy-
clophosphamide (CP) and 4-hydroxycyclophosphamide (HCP)
using NONMEM [abstract 2536]. American Association for
Cancer Research; 1999 Apr 10-14; Philadelphia, 40
95. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide
pharmacokinetics: Correlation with cardiac toxicity and tu-
mor response. J Clin Oncol 1992; 10: 995-1000
96. Nieto Y, Xu XH, Cagnoni PJ, et al. Nonpredictable pharmaco-
kinetic behavior of high-dose cyclophosphamide in combina-
tion with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosurea. Clin
Cancer Res 1999; 5: 747-51
97. Boddy AV, English M, Pearson ADJ, et al. Ifosfamide nephro-
toxicity: limited influence of metabolism and mode of admin-
istration during repeated therapy in pediatrics. Eur J Cancer
1996; 32A: 1179-84
98. Boos J, Silies H, Hohenlochter B, et al. Short-term versus con-
tinuous infusion: no influence on ifosfamide side-chain me-
tabolism. Eur J Cancer 1995; 31A: 2417-8
99. Cerny T, Leyvraz T, von Briel A, et al. Saturable metabolism of
continuous high dose ifosfamide with Mesna and GM-CSF:
a pharmacokinetic study in advanced sarcoma patients. Ann
Oncol 1999; 10: 1087-94
100. Boddy AV, Idle JR. Combined thin-layer chromatography-pho-
tography-densitometry for the quantification of ifosfamide
and its principal metabolites in urine, cerebrospinal fluid and
plasma. J Chromatogr Biomed Appl 1992; 575: 137-42
101. Boddy AV, Proctor M, Simmonds D, et al. Pharmacokinetics,
metabolism and clinical effect of ifosfamide in breast cancer
patients. Eur J Cancer 1995; 31A: 69-76
118. Hartley JM, Hansen L, Harland SJ, et al. Metabolism of ifos-
famide during a 3 day infusion. Br J Cancer 1994; 69: 931-6
119. Corlett SA, Parker D, Chrystyn H. Pharmacokinetics of ifos-
famide and its enantiomers following a single 1-h intravenous
infusion of the racemate in patients with small-cell lung car-
cinoma. Br J Clin Pharmacol 1995; 39: 452-5
120. Roy P, Tretyakov O, Wright J, et al. Stereoselective metabolism
of ifosfamide by human P450s 3A4 and 2B6: favorable
metabolic properties of the R-enantiomer. Drug Metab Disp
1999; 27: 1309-18
121. Walker D, Flinois J-P, Monkman SC, et al. Identification of the
major human hepatic cytochrome P450 involved in activation
and N-dechloroethylation of ifosfamide. Biochem Pharmacol
1994; 47: 1157-63
102. Petros WP and Colvin OM. Metabolic jeopardy with high-dose
cyclophosphamide?: not so fast. Clin Cancer Res 1999; 5:
723-4
103. Wainer IW, Ducharme J, Granvil CP, et al. Ifosfamide stereo-
selective dechloroethylation and neurotoxicity. Lancet 1994;
343: 982-3
122. Murray GI, McKay JA, Weaver RJ, et al. Cytochrome P450
expression is a common molecular event in soft tissue sarco-
mas. J Pathol 1993; 171: 49-52
123. Murray GI, Weaver RJ, Paterson PJ, et al. Expression of xeno-
biotic metabolizing enzymes in breast cancer. J Pathol 1993;
169: 347-53
104. Cerny T, Margison JM, Thatcher N, et al. Bioavailability of
ifosfamide in patients with bronchial carcinoma. Cancer Che-
mother Pharmacol 1986; 18: 261-4
124. Janot F, Massaad L, Ribrag V, et al. Principal xenobiotic-meta-
bolizing enzyme systems in human head and neck squamous
cell carcinoma. Carcinogenesis 1993; 14: 1279-83
105. Wagner T, Drings P. Pharmacokinetics and bioavailability of
125. Goren MP, Wright RK, Pratt CB, et al. Dechloroethylation of
oral ifosfamide. Arzniettelforschung 1986; 36: 878-80
ifosfamide and neurotoxicity. Lancet 1986; II: 1219-20
© Adis International Limited. All rights reserved.
Clin Pharmacokinet 2000 Apr; 38 (4)